Calyxt, Inc. (CLXT)
| Market Cap | 207.33M |
| Revenue (ttm) | 23.85M |
| Net Income (ttm) | -44.84M |
| Shares Out | 37.16M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $5.58 |
| Previous Close | $5.61 |
| Change ($) | -0.03 |
| Change (%) | -0.53% |
| Day's Open | 5.54 |
| Day's Range | 5.31 - 5.66 |
| Day's Volume | 260,553 |
| 52-Week Range | 3.16 - 12.43 |
Calyxt to Host First Quarter 2021 Financial Results Conference Call on Thursday, Ma y 6 , 202 1 at 4 :30 p .m. Eastern Time ROSEVILLE, MN / ACCESSWIRE / April 15, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a pl...
Calyxt (CLXT) delivered earnings and revenue surprises of -32.00% and 77.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
-Shares of Calyxt (NASDAQ:CLXT) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 10.81% year over year to ($0.33), which missed the es...
Continued to Progress Development of Winter Oats and Hemp, Both Targeted at Large Addressable Markets Secured Commitment from ADM to Purchase Remaining 2019 Grain Inventory and All 2020 Grain Production...
Calyxt (CLXT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ROSEVILLE, MN / ACCESSWIRE / March 3, 2021 / Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor conferences during the month of March 2021: Bank of...
World-Renowned Plant-Biochemistry Experts Named to Calyxt's Scientific Advisory Board Chaired by Company Co-Founder Dan Voytas, Ph.D. New Strategic Initiative to Identify High Value Plant-Derived Produc...
Calyxt sells a premium soybean cooking oil Calyno TALEN gene-editing technology is a game-changer Strong management team with proven track record What Calyxt does: Calyxt Inc (NASDAQ:CLXT) is a p...
Calyxt Inc (NASDAQ:CLXT) shares jumped Tuesday after an analyst at Canaccord Genuity Capital markets doubled the firm's price target for the company from $8 to $16 and reiterated a "Buy" rating in a not...
Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Calyxt (CLXT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
These 5 stocks have good reason for further upside.
Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on In...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has contracted to sell all 2020 grain production of its high oleic soybean to AD...
Project delays and slower than anticipated growth contradicts CLXT's business model that claim a speedy development cycle using novel gene-editing technologies.
Calyxt (CLXT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, today announced a research collaboration with NRGene® that includes the adoption of NRGene's cloud-based...
Calyxt, Inc.'s (CLXT) CEO Jim Blome on Q3 2020 Results - Earnings Call Transcript
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, has reported its financial results for the third quarter ended September 30, 2020. Execution of commerci...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has agreed to commercial terms with S&W Seed Company (Nasdaq: SANW), a global ag...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will host a Virtual Analyst Day on Tuesday, November 17, 2020 at 4:00 p.m. Eastern time. The Virtual Ana...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT) (the “Company”), a plant-based technology company, today announced the closing of its previously announced registered direct offering of 3,...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT) (the “Company”), a plant-based technology company, today announced that it has entered into definitive agreements with institutional invest...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has appointed Sarah Reiter as Vice President, Business Development. In this role...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss its resul...
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc.
Calyxt, Inc. (CLXT) CEO James Blome on Q2 2020 Results - Earnings Call Transcript
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc.
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc.
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc.
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced the appointment of current board member Yves Ribeill, Ph.D., as Chairman. This appointment coi...
U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.
Calyxt (CLXT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Calyxt's (CLXT) CEO Jim Blome on Q1 2020 Results - Earnings Call Transcript
Calyxt, Inc.'s (CLXT) CEO Jim Blome on Q4 2019 Results - Earnings Call Transcript
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Falling knives are companies whose share prices have declined more than 59% over the last 52 weeks.
Calyxt, Inc.'s (CLXT) CEO Jim Blome on Q3 2019 Results - Earnings Call Transcript
Calyxt, Inc. (CLXT) CEO Jim Blome on Q2 2019 Results - Earnings Call Transcript
Calyxt (CLXT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calyxt has now commercialized two products from its high-oleic soybean platform and sales should start ramping this year.
Calyxt, Inc. (CLXT) CEO Jim Blome on Q1 2019 Results - Earnings Call Transcript
Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calyxt (CLXT) delivered earnings and revenue surprises of -4.00% and -99.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
About CLXT
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to ... [Read more...]
| Industry Packaged Foods | IPO Date Jul 20, 2017 |
| Stock Exchange NASDAQ | Ticker Symbol CLXT |
Financial Performance
In 2020, Calyxt's revenue was $23.85 million, an increase of 226.91% compared to the previous year's $7.30 million. Losses were -$44.84 million, 13.2% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for Calyxt stock is "Buy." The 12-month stock price forecast is 10.63, which is an increase of 90.50% from the latest price.